文献速递病毒性肝炎

75-84岁慢性丙型肝炎患者经直接抗病毒药物清除病毒后肝细胞癌的发生

Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
PubMed 文献 · J Infect Dis · 2022-01-01

这项多中心队列研究纳入2405例无肝细胞癌病史、经直接抗病毒药物(DAA)实现丙型肝炎病毒(HCV)清除的慢性丙型肝炎患者,中位观察3.5年。75-84岁患者即使治疗后FIB-4指数降至<3.25,肝细胞癌年发生率仍与≥3.25者无显著差异;倾向性评分匹配的495对无肝硬化患者中,75-84岁组累积肝细胞癌发生率显著高于60-74岁组(P = .04)。

要点

  • 75-84岁患者HCV清除后仍属肝细胞癌高危人群,需继续监测。
  • 该年龄段FIB-4指数降至<3.25并不能提示肝细胞癌风险下降。
  • 无肝硬化老年患者中,75-84岁的肝细胞癌累积发生率高于60-74岁。

核心结论

  • 75-84岁慢性丙型肝炎患者经DAA实现HCV清除后仍存在较高的肝细胞癌发生风险,即使FIB-4指数改善至<3.25。

研究设计与样本

  • 多中心队列研究,纳入2405例无肝细胞癌病史、经DAA实现HCV清除的慢性丙型肝炎患者,排除DAA启动1年内发生肝细胞癌者,采用倾向性评分匹配比较75-84岁与60-74岁患者的肝细胞癌风险,中位观察期3.5年。

主要发现

  • 75-84岁且基线FIB-4指数≥3.25的患者中,治疗结束12周时FIB-4≥3.25与<3.25两组的肝细胞癌年发生率无显著差异(2.75/100人年 vs 2.16/100人年)。
  • 60-74岁患者中,治疗结束12周时FIB-4≥3.25与<3.25组的肝细胞癌年发生率分别为3.61/100人年与1.51/100人年(校正风险比2.20;P = .04)。
  • 倾向性评分匹配的495对患者中,无肝硬化者75-84岁组的累积肝细胞癌发生率显著高于60-74岁组(P = .04)。

关键数值与推荐

  • 肝细胞癌年发生率以每100人年(PY)表示:75-84岁FIB-4≥3.25组2.75/100 PY,<3.25组2.16/100 PY。
  • 60-74岁FIB-4≥3.25组3.61/100 PY,<3.25组1.51/100 PY,校正风险比2.20,P = .04。
  • 倾向性评分匹配495对,无肝硬化患者中75-84岁组累积肝细胞癌发生率高于60-74岁组,P = .04。

临床怎么用

  • 对75-84岁经DAA实现HCV清除的慢性丙型肝炎患者,不应因FIB-4指数降至<3.25而放松肝细胞癌监测。
  • 无肝硬化的高龄(75-84岁)患者也应视作肝细胞癌监测的重点人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Direct-acting antiviral (DAA) treatment has revolutionized hepatitis C virus (HCV) care. We aimed to evaluate the risk for the development of hepatocellular carcinoma (HCC) in patients aged 75-84 years with chronic hepatitis C after HCV elimination. METHODS: This multicenter cohort study included 2405 consecutive patients with chronic hepatitis C without a history of HCC who achieved HCV elimination by DAAs. Patients in whom HCC developed within 1 year of DAA initiation were excluded. Propensity score matching analysis was used to evaluate differences in HCC risk between patients aged 75-84 versus 60-74 years. RESULTS: The median observational period was 3.5 years. Among patients aged 75-84 years with a high Fibrosis-4 (FIB-4) index (≥3.25 at baseline), there was no significant difference in the annual incidence of HCCs between groups with an FIB-4 index ≥3.25 (2.75 per 100 person-years [PY]) versus <3.25 (2.16 per 100 PY) at 12 weeks after the end of treatment, unlike the results in those aged 60-74 years (3.61 and 1.51 per 100 PY, respectively) (adjusted hazard ratio, 2.20; P = .04). In 495 pairs matched by propensity score matching, in patients without cirrhosis, the cumulative HCC incidence was significantly higher in the 75-84-year than in the 60-74-year age group (P = .04). CONCLUSIONS: Older patients aged 75-84 years remained at high risk for the development of HCC, even after HCV elimination and the improvement of the FIB-4 index to <3.25.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ogawa E, Nomura H, Nakamuta M, et al. Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals. J Infect Dis. 2022. PMID: 32584386. doi:10.1093/infdis/jiaa359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。